MSCs-engineered biomimetic PMAA nanomedicines for multiple bioimaging-guided and photothermal-enhanced radiotherapy of NSCLC

• Published in: Journal of nanobiotechnology 2021-03, Vol.19 (1), p.80-13, Article 80
• Main Authors: Yin, Yipengchen, Li, Yongjing, Wang, Sheng, Dong, Ziliang, Liang, Chao, Sun, Jiaxin, Wang, Changchun, Chai, Rong, Fei, Weiwei, Zhang, Jianping, Qi, Ming, Feng, Liangzhu, Zhang, Qin
• Format: Article
• Language: English
• Subjects: Active targeting; Bimodal imaging; Biomimetic nanoparticles; Biomimetics; Cancer; Cancer theranostics; Care and treatment; Cell membranes; Complications and side effects; Contrast agents; Efficiency; Erythrocytes; Fluorescence; Genetic aspects; Health aspects; Hyperthermia; Immune system; Intravenous administration; Iron; Irradiation; Lasers; Lung cancer; Lung cancer, Non-small cell; Magnetic resonance imaging; Medical imaging; Membranes; Mesenchyme; Nanoparticles; Non-small cell lung carcinoma; Patient outcomes; Photothermal conversion; Photothermal therapy; Polymerization; Polymethacrylic acid; Radiation therapy; Radiotherapy; Small cell lung carcinoma; Stem cells; Tumors
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-021-00823-6

The recently developed biomimetic strategy is one of the mostly effective strategies for improving the theranostic efficacy of diverse nanomedicines, because nanoparticles coated with cell membranes can disguise as "self", evade the surveillance of the immune system, and accumulate to the tumor sites actively. Herein, we utilized mesenchymal stem cell memabranes (MSCs) to coat polymethacrylic acid (PMAA) nanoparticles loaded with Fe(III) and cypate-an derivative of indocyanine green to fabricate Cyp-PMAA-Fe@MSCs, which featured high stability, desirable tumor-accumulation and intriguing photothermal conversion efficiency both in vitro and in vivo for the treatment of lung cancer. After intravenous administration of Cyp-PMAA-Fe@MSCs and Cyp-PMAA-Fe@RBCs (RBCs, red blood cell membranes) separately into tumor-bearing mice, the fluorescence signal in the MSCs group was 21% stronger than that in the RBCs group at the tumor sites in an in vivo fluorescence imaging system. Correspondingly, the T -weighted magnetic resonance imaging (MRI) signal at the tumor site decreased 30% after intravenous injection of Cyp-PMAA-Fe@MSCs. Importantly, the constructed Cyp-PMAA-Fe@MSCs exhibited strong photothermal hyperthermia effect both in vitro and in vivo when exposed to 808 nm laser irradiation, thus it could be used for photothermal therapy. Furthermore, tumors on mice treated with phototermal therapy and radiotherapy shrank 32% more than those treated with only radiotherapy. These results proved that Cyp-PMAA-Fe@MSCs could realize fluorescence/MRI bimodal imaging, while be used in phototermal-therapy-enhanced radiotherapy, providing desirable nanoplatforms for tumor diagnosis and precise treatment of non-small cell lung cancer.